Liquid Biopsy Market Expanding with Demand for Non-Invasive Diagnostics and Precision Oncology Solutions Worldwide, 2025-2032

The liquid biopsy industry is witnessing rapid advancements driven by its minimally invasive nature and potential in cancer diagnostics and personalized medicine. Increasing adoption across oncology, prenatal testing, and infectious diseases is propelling industry momentum. Cutting-edge technologies such as next-generation sequencing (NGS) and digital PCR are enhancing the accuracy and utility of liquid biopsy assays, transforming clinical diagnostics and monitoring. The Global Liquid Biopsy Market size is estimated to be valued at USD 3.84 billion in 2025 and is expected to reach USD 11.62 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.8% from 2025 to 2032, reflecting strong market growth and expanding market opportunities in this sphere.

Get sample copy:https://www.coherentmarketinsights.com/insight/request-sample/1223

➤Actionable Insights

● The production capacity of liquid biopsy kits surged by 22% in 2024, reflecting manufacturing scale-up to meet rising clinical demand.
● Pricing trends indicate an average cost decline of 8% per annum due to technological innovations and economies of scale, improving affordability in end-use segments.
● Export volumes of liquid biopsy reagents increased by 30% between 2023-2024, with Asia-Pacific emerging as a primary export market.
● Utilization across oncology diagnostics accounted for over 65% of market revenue in 2024, supported by expanding use cases in treatment monitoring and early cancer detection.
● Demand-side indicators reveal rapid growth in liquid biopsy adoption for non-oncological applications, including prenatal genetic testing, which grew 18% in 2024.

❖Market Segment and Regional Coverage

○ By Sample Type: Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), exosomes, microRNAs, and others.
○ By Technology: Next-Generation Sequencing (NGS), Digital PCR, BEAMing, and Others.
○ By Application: Oncology Diagnostics, Prenatal Testing, Infectious Disease Detection, Others.
○ By End-User: Hospitals & Diagnostic Centers, Research Laboratories, Pharmaceutical & Biotechnology Companies, Others.

Regional and Country Analysis:

○ North America: U.S. and Canada
○ Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
○ Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
○ Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
○ Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA.

Get Full Report:https://www.coherentmarketinsights.com/market-insight/liquid-biopsy-market-1223?utm_source=openpr.com&utm_medium=referral&utm

✔Key Players

» Guardant Health
» Roche Diagnostics
» Illumina, Inc.
» Biocept, Inc.
» Bio-Rad Laboratories
» Sysmex Corporation
» QIAGEN N.V.
» F. Hoffmann-La Roche AG
» Thermo Fisher Scientific Inc.
» Adaptive Biotechnologies
» Grail, Inc.
» Exact Sciences Corporation
» ArcherDX, Inc.
» Natera, Inc.
» Singlera Genomics
» Laboratory Corporation of America Holdings

» Guardant Health implemented strategic collaborations with major oncology centers in the U.S. throughout 2024, accelerating clinical adoption and achieving a 15% revenue uplift.
» Roche Diagnostics expanded its portfolio with cutting-edge NGS-based liquid biopsy assays in 2025, which strengthened its footprint in Europe and Asia-Pacific markets.
» Illumina partnered with pharmaceutical companies to co-develop companion diagnostics leveraging liquid biopsy, fostering integrated market growth strategies.

➤Growth Factors

✓ Increasing incidence and early detection initiatives for cancers such as lung, breast, and colorectal play a pivotal role in market growth, with lung cancer liquid biopsy procedures seeing a 25% rise in usage in 2024.
✓ Government and private funding for precision oncology and non-invasive diagnostic tools reached USD 400 million globally in 2024, fueling innovation and commercialization.
✓ Rising awareness of liquid biopsy's potential to guide targeted therapies is expanding demand among healthcare providers, especially in North America and Europe.
✓ The reduction in sequencing costs by nearly 30% since 2023 has removed financial barriers, amplifying market revenue opportunities.

❖Market Trends

⇨ Integration of AI and machine learning into liquid biopsy data analysis is enhancing interpretative accuracy, with startups demonstrating a 35% improvement in diagnostic yield in 2024.
⇨ Increasing adoption of multi-cancer early detection (MCED) tests based on liquid biopsy is reshaping oncology diagnostics, gaining regulatory approvals and clinical traction in 2025.
⇨ Expansion of point-of-care liquid biopsy platforms is facilitating decentralized testing models, especially in Asia Pacific markets.
⇨ Collaborative research projects between biotech firms and academic institutions are accelerating the development of novel biomarkers and assay platforms.

✒Key Takeaways

→ Liquid Biopsy Market segments dominated by Circulating Tumor DNA (ctDNA) reflect high sensitivity and clinical acceptance.
→ Next-Generation Sequencing (NGS) technology drives major market revenue due to its multiplexing capacity.
→ Oncology diagnostics are the largest application segment benefiting from advancements in early cancer detection.
→ North America continues to be a leading region with robust clinical infrastructure and reimbursement frameworks.
→ Asia Pacific exhibits dynamic growth led by China and India's expanding healthcare investments and favorable regulatory pathways.
→ Europe's diversified pharmaceutical base and precision medicine initiatives underpin sustained market development.

Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/1223

❓Frequently Asked Questions

1. Who are the dominant players in the Liquid Biopsy market?
The Liquid Biopsy market is led by prominent companies such as Guardant Health, Roche Diagnostics, Illumina, and Biocept, which leverage innovation and strategic partnerships to expand their market presence.

2. What will be the size of the Liquid Biopsy market in the coming years?
The market size for Liquid Biopsy is projected to grow from USD 3.84 billion in 2025 to USD 11.62 billion by 2032, with a CAGR of 17.8%, reflecting strong market momentum and expanding adoption.

3. Which end-user industry has the largest growth opportunity?
Oncology diagnostics currently offers the largest growth opportunity due to expanding use cases in early cancer detection and treatment monitoring, supported by technological advancements and clinical validation.

4. How will market development trends evolve over the next five years?
Trends indicate greater integration of AI analytics, multi-cancer detection capabilities, and point-of-care liquid biopsy platforms, driving market diversification and increased accessibility.

5. What is the nature of the competitive landscape and challenges in the Liquid Biopsy market?
The competitive landscape is characterized by technological innovation, strategic collaborations, and regulatory approvals; challenges include high development costs and the need for clinical validation across diverse applications.

6. What go-to-market strategies are commonly adopted in the Liquid Biopsy market
Companies frequently adopt strategies including partnerships with oncology centers, co-development of companion diagnostics, expansion of geographic footprint, and pricing optimization to drive market share and business growth.

About Us:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

📌Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
📞U.S.: + 12524771362
📞U.K.: +442039578553
📞AUS: +61-2-4786-0457
📞INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

This release was published on openPR.